EnteroMedics has developed VBLOC® vagal blocking therapy, a first-in-class weight loss treatment for obesity and related co-morbidities. VBLOC Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to control both hunger and fullness by blocking the primary nerve which regulates the digestive system. VBLOC Therapy is designed to address the lifelong challenge of obesity by empowering people to take a positive path toward weight loss without compromising their lifestyle.
EnteroMedics completed an Initial Public Offering in October 2007 (NASDAQ:ETRM).